Dr. Jad Kebbe, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 200
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
OK license 31942 -
Critical Care Medicine (Internal Medicine) Physician
OK license 31942
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- O U Medical Center Oklahoma City, OK
- Mercy Hospital Oklahoma City, Inc Oklahoma City, OK
- Memorial Health Lawton, OK
- Integris Health Edmond Hospital Edmond, OK
- Integris Health Enid Hospital Enid, OK
Medical groups
- Ou Health PArtners Inc (1,184 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 200
- Services billed
- 1,066
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 156 | 65 |
| Established patient office or other outpatient visit, 40-54 minutes | 132 | 86 |
| Test to examine how well the lungs exchange gases | 111 | 66 |
| Test to determine lung volumes using sensors | 93 | 63 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 89 | 58 |
| Test to measure expiratory airflow and volume | 79 | 55 |
| Established patient office or other outpatient visit, 30-39 minutes | 57 | 43 |
| Test to measure largest amount of air breathed in an out | 35 | 32 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 29 | 26 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 27 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ofev (nintedanib esylate) | 313 |
| Prednisone Other prescribers in Oklahoma City, OK | 156 |
| Mycophenolate Mofetil Other prescribers in Oklahoma City, OK | 121 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Oklahoma City, OK | 100 |
| Pirfenidone | 67 |
| Montelukast Sodium Other prescribers in Oklahoma City, OK | 64 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Oklahoma City, OK | 54 |
| Xolair (omalizumab) | 51 |
| Azathioprine Other prescribers in Oklahoma City, OK | 49 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Oklahoma City, OK | 41 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 8 payments worth $866 in total to this clinician.
| Vertex Pharmaceuticals Incorporated | $450 |
|---|---|
| United Therapeutics Corporation | $363 |
| GlaxoSmithKline, LLC. | $38.44 |
| Amgen Inc. | $14.75 |
| Consulting Fee | $450 |
|---|---|
| Food and Beverage | $416 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Vertex Pharmaceuticals Incorporated Aug 25, 2025 | Consulting Fee | $450 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $640,827 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c. - Idiopathic Pulmonary Fibrosis Prospective Outcome Registry
Boehringer Ingelheim Pharmaceuticals, Inc. - Phase 2 Double Blind Randomized Study in IPF and SSc ILD
Genentech, Inc. - A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
E.r. Squibb & Sons, L.l.c. - Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782 - Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
United Therapeutics Corporation · Enrolling by invitation · NCT04905693 - Ph iii study to evaluate the efficacy and safety of astegolimab in copd
Genentech, Inc. - A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with id…
Boehringer Ingelheim Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.